Talis Biomedical Corp (TLIS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -21,884 | -13,035 | -62,007 | -48,547 | -32,865 |
| Depreciation Amortization | 346 | 262 | 770 | 559 | 342 |
| Accounts receivable | 50 | 43 | 259 | 304 | -224 |
| Accounts payable and accrued liabilities | 2,451 | 2,280 | -2,429 | -1,071 | -1,307 |
| Other Working Capital | -4,267 | 371 | -3,424 | -3,893 | -3,935 |
| Other Operating Activity | 5,547 | 3,652 | 13,591 | 10,765 | 7,250 |
| Operating Cash Flow | $-17,757 | $-6,427 | $-53,240 | $-41,883 | $-30,739 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 114 | 30 | -486 | -579 | -509 |
| Investing Cash Flow | $114 | $30 | $-486 | $-579 | $-509 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 2 | 2 | 33 | 33 | 33 |
| Financing Cash Flow | $2 | $2 | $33 | $33 | $33 |
| Beginning Cash Position | 78,274 | 78,274 | 131,967 | 131,967 | 131,967 |
| End Cash Position | 60,633 | 71,879 | 78,274 | 89,538 | 100,752 |
| Net Cash Flow | $-17,641 | $-6,395 | $-53,693 | $-42,429 | $-31,215 |
| Free Cash Flow | |||||
| Operating Cash Flow | -17,757 | -6,427 | -53,240 | -41,883 | -30,739 |
| Capital Expenditure | N/A | N/A | -486 | -579 | -509 |
| Free Cash Flow | -17,757 | -6,427 | -53,726 | -42,462 | -31,248 |